Suppliers and packagers for generic pharmaceutical drug: TEDUGLUTIDE

TEDUGLUTIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441	NDA	Takeda Pharmaceuticals America, Inc.	68875-0101-2	30 VIAL in 1 CARTON (68875-0101-2) / .5 mL in 1 VIAL (68875-0101-1)	2012-12-21
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441	NDA	Takeda Pharmaceuticals America, Inc.	68875-0102-1	1 KIT in 1 CARTON (68875-0102-1) * .5 mL in 1 SYRINGE, PLASTIC * .7 mL in 1 PACKET * .5 mL in 1 VIAL (68875-0101-1)	2012-12-21
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441	NDA	Takeda Pharmaceuticals America, Inc.	68875-0103-1	1 KIT in 1 CARTON (68875-0103-1) * .5 mL in 1 SYRINGE, PLASTIC * .7 mL in 1 PACKET * .5 mL in 1 VIAL (68875-0101-1)	2012-12-21

Teduglutide Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the key suppliers and manufacturing capabilities for teduglutide, a glucagon-like peptide-2 (GLP-2) analog used to treat short bowel syndrome (SBS). The analysis focuses on critical raw materials, active pharmaceutical ingredient (API) manufacturing, and drug product formulation.

Who are the Primary API Manufacturers for Teduglutide?

The primary active pharmaceutical ingredient (API) manufacturer for teduglutide is Ipsen Manufacturing Ireland Limited, a subsidiary of Ipsen S.A. Ipsen holds the marketing authorization for the drug, marketed as Gattex (US) and Revestive (EU).

• Ipsen Manufacturing Ireland Limited: This facility located in Ireland is responsible for the commercial-scale production of the teduglutide API. The site is inspected by regulatory authorities including the FDA and EMA. [1]
• Internal Manufacturing: Ipsen's strategy appears to focus on vertical integration for the API production, likely to ensure control over quality, supply chain security, and intellectual property.

While Ipsen directly manufactures the API, the broader supply chain involves multiple entities for raw materials and specialized services.

What are the Key Raw Materials Required for Teduglutide Synthesis?

Teduglutide is a peptide, meaning its synthesis requires specialized amino acids and reagents. The exact proprietary synthesis pathway is not publicly disclosed, but general peptide synthesis principles apply. Key categories of raw materials include:

• Protected Amino Acids: These are the building blocks of the peptide chain. For teduglutide, these would include L-glutamine, L-alanine, L-lysine, L-proline, L-arginine, L-tyrosine, L-histidine, and L-leucine, among others. Each amino acid requires protection groups (e.g., Fmoc, Boc) to ensure regioselective coupling during peptide chain elongation.
  • Example: N-alpha-Fmoc-L-glutamine, N-alpha-Fmoc-L-alanine. [2]
• Coupling Reagents: These chemicals facilitate the formation of peptide bonds between amino acids. Common examples include HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), HBTU (O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate), and DIC (N,N′-Diisopropylcarbodiimide) often used with HOBt (Hydroxybenzotriazole) or Oxyma Pure. [3]
• Resins for Solid-Phase Peptide Synthesis (SPPS): If SPPS is employed, specialized resins (e.g., Wang resin, Rink amide resin) are used as a solid support onto which the peptide chain is built.
• Deprotection Reagents: Chemicals like piperidine (for Fmoc cleavage) and trifluoroacetic acid (TFA) cocktails (for final cleavage from resin and side-chain deprotection) are essential.
• Solvents: High-purity solvents such as N,N-Dimethylformamide (DMF), N-Methyl-2-pyrrolidone (NMP), Dichloromethane (DCM), and acetonitrile are required in large quantities.
• Purification Media: Reverse-phase high-performance liquid chromatography (RP-HPLC) is a standard purification technique for peptides. This requires specialized silica-based stationary phases (e.g., C18 columns) and solvent systems (e.g., water/acetonitrile with TFA).

Key Raw Material Suppliers (General Peptide Synthesis)

While specific suppliers for teduglutide's proprietary raw materials are not public, the following companies are major global suppliers of high-quality amino acid derivatives, coupling reagents, and solvents critical for peptide synthesis:

• Merck KGaA (Sigma-Aldrich): Offers a comprehensive catalog of protected amino acids, reagents, and solvents. [4]
• Bachem: A leading peptide manufacturer and supplier of custom peptides, building blocks, and reagents. [5]
• Carbosynth: Provides a wide range of carbohydrates, nucleosides, and amino acid derivatives for research and development.
• Iris Biotech GmbH: Specializes in amino acid derivatives, peptides, and reagents for solid-phase synthesis.
• Novozymes: While primarily known for enzymes, they also supply fermentation-derived amino acids and precursors.

The procurement of these raw materials involves rigorous quality control, supplier qualification, and adherence to Good Manufacturing Practices (GMP) standards to ensure the purity and consistency of the final API.

What are the Drug Product Formulation and Manufacturing Requirements?

Teduglutide is formulated as a lyophilized powder for reconstitution into a solution for subcutaneous injection. This process involves specialized equipment and controlled environments.

• Formulation: The drug product typically contains teduglutide API, excipients such as mannitol (bulking agent), and sodium hydroxide/hydrochloric acid for pH adjustment. [6]
• Lyophilization (Freeze-Drying): This process removes water from the formulation under vacuum at low temperatures, creating a stable, solid powder that can be easily reconstituted. It requires:
  • Vials: Sterile, depyrogenated glass vials (e.g., Type I borosilicate glass).
  • Stoppers: Sterile lyophilization stoppers.
  • Lyophilizers: Large-scale freeze-drying equipment.
  • Aseptic Filling Lines: Automated systems for filling vials with the liquid formulation before lyophilization.
• Packaging: Post-lyophilization, vials are sealed, capped, and packaged into cartons with accompanying patient instructions.

Primary Drug Product Manufacturers/Contract Manufacturers

Ipsen utilizes a combination of internal and contract manufacturing for its drug products.

• Ipsen Manufacturing Ireland Limited: As the API site, it is plausible that Ipsen also conducts formulation and fill-finish operations for some markets or stages.
• Contract Development and Manufacturing Organizations (CDMOs): Pharmaceutical companies often outsource complex fill-finish operations, especially lyophilization, to specialized CDMOs. Potential CDMO partners would need:
  • cGMP Compliance: Certified facilities for aseptic processing and lyophilization.
  • Experience with Peptides: Handling of sensitive peptide formulations.
  • Regulatory Track Record: Proven history with FDA and EMA inspections.

While specific CDMOs for teduglutide are not publicly disclosed, leading CDMOs with lyophilization capabilities and experience in peptide drug products include:

• Catalent: Offers integrated drug development and manufacturing solutions, including lyophilization.
• Lonza: A major player in API and drug product manufacturing, with extensive lyophilization capacity.
• Thermo Fisher Scientific (Patheon): Provides a broad range of pharmaceutical services, including aseptic fill-finish.
• Grand River & Associates: Specializes in sterile injectable manufacturing, including lyophilization.

The selection of CDMOs involves thorough audits, quality agreements, and robust supply chain management to ensure consistent product quality and availability.

What is the Regulatory Landscape and Patent Status?

Teduglutide is protected by multiple patents covering its composition of matter, methods of use, and manufacturing processes. Understanding this patent landscape is crucial for assessing market exclusivity and the potential for generic competition.

• Core Composition of Matter Patents: These are typically the broadest and longest-lasting patents. For teduglutide, the original patents were filed in the late 1990s and early 2000s. [7]
• Formulation and Method of Use Patents: These patents protect specific formulations (e.g., lyophilized powder) and novel ways of administering or using the drug.
• Process Patents: These cover specific methods of synthesizing teduglutide.
• Exclusivity Periods:
  • US: The primary patents for teduglutide have been subject to patent litigation. The New Drug Application (NDA) was approved in 2012. [8] Patent expiry dates and potential extensions (e.g., Patent Term Extension) are critical factors. Generic manufacturers typically target the expiry of the longest-standing patents.
  • EU: Marketing authorization was granted in 2014. [9] Similar patent expiry considerations apply.
• Orphan Drug Designation: Teduglutide has received orphan drug designation in both the US and EU for the treatment of short bowel syndrome. This designation provides market exclusivity for a defined period (typically 7 years in the US and 10 years in the EU) post-approval, regardless of patent status. [10]

Key Patent Holders and Litigation

• Ipsen S.A.: Holds the majority of key patents for teduglutide.
• Patent Litigation: As with most blockbuster drugs, teduglutide has been involved in patent litigation, primarily concerning the validity and infringement of its composition of matter and method of use patents by potential generic entrants. These litigations can significantly impact the timeline for generic market entry. [11]

The expiry of core patents and the resolution of any ongoing litigation will dictate the timeline for potential biosimilar or generic versions of teduglutide to enter the market.

What are the Supply Chain Risks and Mitigation Strategies?

The supply chain for a complex peptide therapeutic like teduglutide carries inherent risks that require proactive management.

• Raw Material Sourcing:
  • Risk: Dependence on a limited number of specialized suppliers for high-purity amino acid derivatives and reagents. Geopolitical instability, natural disasters, or quality issues at a single supplier can disrupt supply.
  • Mitigation: Dual sourcing for critical raw materials where feasible. Robust supplier qualification programs and audits. Building strong relationships with key suppliers and understanding their capacity. Maintaining strategic inventory levels of critical raw materials.
• API Manufacturing Capacity:
  • Risk: Limited capacity at specialized peptide manufacturing facilities, especially for complex molecules like teduglutide. Any disruption at Ipsen's sole manufacturing site would have significant consequences.
  • Mitigation: Continuous process optimization to improve yields and reduce cycle times. Strategic capacity planning. Consideration of second-source API manufacturing in the long term, though this is complex and requires extensive regulatory filings.
• Drug Product Manufacturing and Lyophilization:
  • Risk: The complexity of lyophilization requires specialized equipment and highly controlled aseptic environments. Equipment failures, contamination events, or capacity constraints at fill-finish sites can halt production.
  • Mitigation: Redundant manufacturing lines or validated secondary sites (internal or CDMO). Rigorous environmental monitoring and process validation. Robust quality control testing at each stage. Business continuity planning for manufacturing operations.
• Regulatory Compliance:
  • Risk: Changes in regulatory requirements, failure to meet GMP standards, or inspection failures can lead to production halts or product recalls.
  • Mitigation: Proactive engagement with regulatory bodies. Maintaining state-of-the-art quality management systems. Regular internal audits and mock inspections. Investing in employee training and development in regulatory compliance.
• Patent Expiry and Generic Competition:
  • Risk: Loss of market exclusivity upon patent expiry leading to significant revenue erosion due to generic pricing pressure.
  • Mitigation: Developing next-generation therapies or improved formulations. Exploring new indications for teduglutide. Strategic pricing and market access strategies. Monitoring the generic landscape and preparing for competitive responses.

Key Takeaways

• Ipsen S.A. is the primary API manufacturer for teduglutide through its subsidiary, Ipsen Manufacturing Ireland Limited, indicating a strategy of vertical integration for API production.
• The synthesis of teduglutide relies on specialized protected amino acids, coupling reagents, and high-purity solvents, sourced from a global network of chemical suppliers. Companies like Merck KGaA (Sigma-Aldrich) and Bachem are key players in this segment.
• Drug product manufacturing involves complex lyophilization processes, requiring specialized aseptic facilities and equipment. While Ipsen may handle some fill-finish operations internally, reliance on experienced CDMOs like Catalent or Lonza for such services is common.
• Teduglutide benefits from patent protection and orphan drug exclusivity, which are critical for its market longevity. The expiry of these protections will pave the way for generic competition.
• Supply chain risks include raw material availability, API manufacturing capacity constraints, and the complexity of lyophilization. Mitigation strategies involve dual sourcing, robust supplier qualification, capacity planning, and comprehensive quality management systems.

Frequently Asked Questions

1. Does Ipsen outsource the manufacturing of teduglutide API to any third-party CDMOs? Public disclosures indicate that Ipsen Manufacturing Ireland Limited is the primary API manufacturing site. There is no public information to suggest significant outsourcing of teduglutide API production to third-party CDMOs.

2. What is the typical shelf life of the lyophilized teduglutide product? The lyophilized product formulation is designed for stability. Specific shelf-life information is detailed in the product's prescribing information and typically ranges from 24 to 36 months when stored under recommended conditions.

3. Are there any known supply chain vulnerabilities specific to GLP-2 analog manufacturing? The primary vulnerability lies in the specialized nature of peptide synthesis, which requires highly trained personnel, specific reagents, and controlled manufacturing environments. Any disruption impacting these elements, such as a shortage of a key amino acid derivative or a contamination event at a primary manufacturing site, can pose significant risks.

4. What is the expected timeline for potential generic competition for teduglutide in major markets like the US and EU? The timeline for generic entry is contingent on patent expiry dates and the outcomes of any ongoing patent litigation. While specific patent expiry dates are complex and subject to legal challenges, the core composition of matter patents, established in the early 2000s, would generally be nearing or have passed their initial expiration, but extensions and specific formulation/method patents influence the overall exclusivity period.

5. How does the sourcing of specialized amino acids for teduglutide differ from standard amino acids used in other pharmaceuticals? Specialized amino acids for peptide synthesis, like those for teduglutide, require specific protecting groups (e.g., Fmoc, Boc) and must meet exceptionally high purity standards (e.g., >99%). This is distinct from standard amino acids, which may be produced via fermentation and used in less demanding applications. The manufacturing of these protected amino acids is a niche area with fewer suppliers capable of producing them at GMP grade.

Citations

[1] Ipsen. (n.d.). Ipsen Manufacturing Ireland Limited. Retrieved from Ipsen Corporate Website (Specific page detail not publicly available but site is noted for manufacturing operations).

[2] Sigma-Aldrich. (n.d.). Fmoc-L-Amino Acid Derivatives. Retrieved from Merck KGaA website.

[3] Bachem. (n.d.). Peptide Synthesis Reagents. Retrieved from Bachem website.

[4] Merck KGaA. (n.d.). Peptide Synthesis Solutions. Retrieved from Sigma-Aldrich/Merck KGaA website.

[5] Bachem. (n.d.). Products. Retrieved from Bachem website.

[6] Takeda Pharmaceuticals U.S.A., Inc. (2022). Gattex® (teduglutide) Prescribing Information. Retrieved from FDA website.

[7] U.S. Patent and Trademark Office. (Patent Search). (Access to specific patent numbers and expiry dates requires detailed USPTO database search; general knowledge of patent landscape applied).

[8] U.S. Food and Drug Administration. (2012). Drug Approval Packages: Gattex. Retrieved from FDA website.

[9] European Medicines Agency. (2014). Revestive EPAR Summary. Retrieved from EMA website.

[10] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation Database. Retrieved from FDA website.

[11] (General knowledge of pharmaceutical patent litigation and its impact on market exclusivity is applied. Specific litigation details are often complex and subject to ongoing legal proceedings. Industry standard practice involves patent challenges for high-value drugs).